We ran a pharmacokinetic sub-study within the CHAPAS-4 trial, which found that darunavir exposures in the trial are within a safe range. The sub-study included African children with #HIV taking once-daily darunavir/ritonavir for 2nd line treatment.

Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV

AbstractBackground. Darunavir is a potent HIV protease inhibitor with a high barrier to resistance. We conducted a nested pharmacokinetic sub-study within